Furthermore, we investigated immunohistochemical FAP and glucose transporter 1 (GLUT1) expression from tumor samples of our patient cohort and assessed the impact of 68Ga-FAPI-46 PET/CT on cholangiocarcinoma management. This evidence concerns the gene FAP and cholangiocarcinoma.